Victory Capital Management Inc. lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,917,551 shares of the medical equipment provider's stock after purchasing an additional 24,358 shares during the period. Victory Capital Management Inc. owned 2.18% of Hologic worth $354,506,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. General Partner Inc. acquired a new position in Hologic during the 4th quarter worth approximately $26,000. Groupama Asset Managment raised its stake in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the period. Institutional investors own 94.73% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on HOLX. BNP Paribas raised Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Stephens reaffirmed an "overweight" rating and set a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Finally, Evercore ISI lowered their price objective on Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a research note on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $84.62.
Check Out Our Latest Stock Report on HOLX
Hologic Stock Performance
Shares of HOLX stock traded up $2.04 during trading on Friday, hitting $64.54. The company's stock had a trading volume of 3,005,458 shares, compared to its average volume of 2,354,176. The company has a market cap of $14.48 billion, a PE ratio of 20.36, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average of $68.35 and a 200-day moving average of $75.46. Hologic, Inc. has a 52 week low of $61.70 and a 52 week high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.
Hologic Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Stories
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
